Oragenics Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics Inc. on December 11, 2025. The report details executive compensation adjustments and equity awards approved by the Board of Directors on the same date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive and director compensation arrangements.
Material Changes and Compensation Details
- CEO Salary Increase: The Board authorized a 5% increase in the annual base salary of CEO Janet Huffman, effective January 1, 2026. The salary rises from $325,000 to $341,250.
- CEO Performance Bonus: Based on performance goals, the Board awarded Ms. Huffman a bonus of $110,500.
- CEO Stock Options: Ms. Huffman was granted options to purchase 250,000 shares at an exercise price of $0.93 per share. These options vest in equal annual installments over three years, contingent on continued employment.
- Director Stock Options: Each Non-Employee Director received an award to purchase 125,000 shares at $0.93 per share, which vested immediately.
- New Director Onboarding Award: Natasha Giordano, appointed to the Board on September 1, 2025, received an onboarding stock option valued at $30,000, which vested immediately.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The stock option agreements include standard provisions for earlier vesting upon a change in control.
Key Facts for Investor Verification
- Verify the total dilution impact of the 250,000 CEO options and 125,000 options per Non-Employee Director against the current share count.
- Confirm the cash outflow impact of the $110,500 CEO bonus and the increased annual salary obligation starting in 2026.
- Review the Company's 2021 Equity Incentive Plan to ensure sufficient shares remain available for these grants.
- Check the closing stock price of $0.93 on December 11, 2025, to validate the exercise price of the new awards.